Looking forward to the September Webinar/next quarterly for the...

Looking forward to the September Webinar/next quarterly for the data to support the companies movement forward.

Clarification on the immunotherapies division may do it, I'm afraid 'on hold' will not quite cover it.

Also may need to assure the market/investors that funds, via debt perhaps, on the cards. All comes down to 'projected sales', too iffy, imo, to rely on.

In regards to the 'halo' affect on sales of up and coming products, do not believe, imo, that this means it will happen in the short term future, certainly shouldn't have to wait for 8 years like the CardioCel, still will not magically happen in the short term future, imo.

Believe the company may be stretching itself too thin ...... implemention of new products and World wide market penetration is a costly endeavour for a relative 'minnow' in this field.

The sp continues to languish, sitting again on former lowes, the disconnect between fundamentals and the current sp is very concerning, has gone on for too long, could understand if Code Red had not yet been implemented!

That 'patience' is required may be alright for us on HC, what that means to the company is this: patience requires plenty of time, the company does not have the luxury of this, imo, without 'projected sales' going 'gang busters' and outstripping cash burn, cash on hand, from the next quarter onwards will be vital.

Very,very, interesting times ahead .....